GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Inventories, Work In Process

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Inventories, Work In Process : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Inventories, Work In Process?

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Kiora Pharmaceuticals's work in process for the quarter that ended in Dec. 2023 was $0.00 Mil.


Kiora Pharmaceuticals Inventories, Work In Process Historical Data

The historical data trend for Kiora Pharmaceuticals's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Inventories, Work In Process Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.


Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.
Executives
Carmine N. Stengone director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca officer: EVP of Finance C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler officer: Interim CFO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
David Hollander director C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem director, officer: President and CEO C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels officer: Chief Development Officer C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro director C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron director 75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr officer: Acting CEO C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Headlines

From GuruFocus